The Forteo class action lawsuit centers on claims that Eli Lilly’s osteoporosis drug causes osteosarcoma, a rare and aggressive bone cancer. Patients across the country are filing legal claims in 2026, alleging the pharmaceutical giant hid known cancer risks for years.
If you took Forteo and later received a cancer diagnosis, you may be eligible for compensation. This article breaks down the 2026 lawsuit status, settlement estimates, who qualifies, filing deadlines, and what you should expect going forward.
Here’s a number worth knowing: FDA data shows Forteo carried a black box warning about bone cancer risk since its 2002 approval. That warning came from animal studies showing tumor growth in rats. And yet, millions of prescriptions were written.
You’ll find every detail you need below, from the latest case updates to estimated payouts.
Forteo Class Action Lawsuit
The Forteo class action lawsuit refers to legal actions filed by patients who developed bone cancer or osteosarcoma after using the osteoporosis drug Forteo (teriparatide). These cases accuse Eli Lilly of failing to adequately warn patients and doctors about cancer risks tied to the medication.
Forteo hit the market in 2002 as an injectable treatment for severe osteoporosis. From the start, the drug carried a black box warning, the FDA’s most serious label alert. That warning was based on lab studies where rats developed osteosarcoma after receiving teriparatide.
Despite the warning, plaintiffs argue Eli Lilly downplayed the risk to human patients. They claim the company aggressively marketed Forteo without enough emphasis on the potential for deadly bone tumors.
| Detail | Info |
|---|---|
| Drug Name | Forteo (teriparatide) |
| Manufacturer | Eli Lilly and Company |
| FDA Approval | November 2002 |
| Primary Allegation | Failure to warn about osteosarcoma risk |
| Warning Type | Black box warning since approval |
Most of these cases are structured as individual product liability claims rather than a single certified class action. The distinction matters because it affects how much each person could potentially recover.
Lawsuits have been filed in both state and federal courts. Plaintiffs come from dozens of states, and attorneys are working to consolidate some cases for efficiency.
Forteo Lawsuit Update 2026
The Forteo lawsuit in 2026 is seeing increased activity as more plaintiffs come forward and attorneys push for case consolidation. Courts are processing a growing number of claims from patients diagnosed with osteosarcoma and other bone cancers after Forteo use.
As of early 2026, several key developments are shaping the litigation:
- New filings continue at a steady pace across federal districts
- Attorneys are working toward potential MDL (multidistrict litigation) consolidation
- Expert discovery on the link between teriparatide and human osteosarcoma is progressing
- Eli Lilly has maintained its defense that the black box warning was adequate
No bellwether trial date has been set yet. But legal observers expect that if an MDL is established, the first test cases could be scheduled for late 2026 or early 2027.
The pharmaceutical company continues to argue that its warning label covered the cancer risk. Plaintiffs counter that the label language minimized the danger and didn’t reflect the full scope of evidence from post-market reports.
Discovery is a critical phase right now. Internal Eli Lilly documents about marketing decisions, safety data suppression, and communication with the FDA could become pivotal evidence.
Key Takeaway: The Forteo lawsuit is gaining momentum in 2026, with more filings, advancing discovery, and potential MDL consolidation on the horizon.
Is There a Class Action Lawsuit Against Forteo
Yes, legal actions have been filed against Forteo, though the cases are primarily structured as mass tort litigation rather than a certified class action. The difference between these two legal paths matters for anyone considering a claim.
In a class action, one lawsuit represents an entire group of people. Everyone in the class gets the same outcome. In a mass tort, each plaintiff files an individual claim. That means your payout depends on your specific injuries, medical history, and evidence.
Here’s why that distinction is good news for Forteo plaintiffs: individual claims often result in higher compensation. A person with an osteosarcoma diagnosis could recover more than they would splitting a class-wide settlement pot equally.
| Feature | Class Action | Mass Tort |
|---|---|---|
| Case Structure | One case for all | Individual claims grouped |
| Settlement Distribution | Equal split | Based on individual injuries |
| Plaintiff Control | Limited | More control over your case |
| Typical Payout | Lower per person | Potentially higher per person |
| Current Forteo Status | Not certified as class action | Cases proceeding individually |
Some attorneys still use the phrase “class action” loosely when describing Forteo litigation. The accurate term for most pending Forteo cases is mass tort or product liability litigation.
If enough cases are filed in federal court, a judicial panel could consolidate them into an MDL for pretrial proceedings. This keeps individual claims intact while streamlining the process.
Forteo Osteosarcoma Lawsuit
The Forteo osteosarcoma lawsuit represents the most serious category of claims in this litigation. Osteosarcoma is a rare, aggressive bone cancer, and plaintiffs say Forteo directly caused it.
Osteosarcoma typically affects young people. But among Forteo users, the cancer has appeared in adults who had no prior risk factors. This pattern is central to the plaintiffs’ argument.
The cancer connection dates back to preclinical testing. Rats given teriparatide developed osteosarcoma at alarming rates. The FDA required Eli Lilly to include a black box warning because of these findings. But the question in court is whether the warning went far enough.
Several reported cases involve patients who:
- Used Forteo for the maximum recommended 24-month treatment period
- Had no family history of bone cancer
- Were diagnosed with osteosarcoma within 2 to 10 years of starting Forteo
- Underwent aggressive surgery, chemotherapy, or amputation
The survival rate for osteosarcoma varies widely. When caught early, about 60% to 70% of patients survive five years. But for those diagnosed late, the prognosis is grim.
Plaintiffs argue that Eli Lilly possessed evidence suggesting the cancer risk extended to humans, not just rats. They claim the company should have pulled the drug or restricted its use far more aggressively.
Key Takeaway: Osteosarcoma cases form the backbone of Forteo litigation, and plaintiffs allege that Eli Lilly knew the cancer risk was real for human patients.
Forteo Bone Cancer Lawsuit
The Forteo bone cancer lawsuit encompasses claims beyond just osteosarcoma, including other types of bone tumors and malignancies reported by former Forteo users. Not every plaintiff has an osteosarcoma diagnosis, but many allege other bone cancers linked to the drug.
Bone cancers beyond osteosarcoma that have surfaced in litigation include:
- Chondrosarcoma (cartilage cancer)
- Ewing sarcoma in rare adult cases
- Undifferentiated pleomorphic sarcoma of bone
- Benign bone tumors that required surgical intervention
Each type of bone cancer presents different challenges in proving causation. Osteosarcoma has the strongest preclinical evidence because of the rat studies. Other bone cancers require more expert testimony to establish the Forteo connection.
Think of it like a bullseye target. Osteosarcoma sits at the center with the clearest evidence. Other bone cancers sit in outer rings where the link exists but requires more scientific support.
| Cancer Type | Link to Forteo | Evidence Strength |
|---|---|---|
| Osteosarcoma | Direct preclinical evidence | Strong |
| Chondrosarcoma | Post-market reports | Moderate |
| Other bone sarcomas | Emerging case reports | Developing |
| Benign bone tumors | Limited reports | Under review |
Attorneys handling these cases typically work with oncologists and toxicologists who can connect the dots between teriparatide exposure and tumor development.
Regardless of the specific bone cancer type, all plaintiffs share a common claim: Eli Lilly failed to protect them from foreseeable harm.
Forteo Side Effects Lawsuit
The Forteo side effects lawsuit covers a broader range of health problems beyond cancer. While bone cancer grabs the headlines, many plaintiffs report other serious adverse effects that they blame on the drug.
Common side effects that have appeared in legal filings include:
- Hypercalcemia (dangerously high calcium levels)
- Severe joint and muscle pain
- Dizziness and fainting spells
- Leg cramps
- Nausea and vomiting
- Injection site reactions
- Heart palpitations
For most patients, these side effects alone wouldn’t trigger a lawsuit. But when they’re combined with inadequate warnings or when they cause lasting damage, they become legally actionable.
Some plaintiffs report that their doctors never mentioned the black box warning. Others say their physicians prescribed Forteo for longer than the recommended two-year maximum, a practice that may increase risk.
The side effects claims often appear alongside the cancer allegations. A plaintiff might sue for osteosarcoma as the primary injury and list hypercalcemia and chronic pain as additional damages.
| Side Effect | Severity Level | Reported Frequency |
|---|---|---|
| Osteosarcoma | Life-threatening | Rare but documented |
| Hypercalcemia | Serious | Uncommon |
| Joint/muscle pain | Moderate | Common |
| Dizziness | Moderate | Common |
| Nausea | Mild to moderate | Common |
| Injection reactions | Mild | Very common |
Eli Lilly’s defense points to the drug label as covering these risks. Plaintiffs counter that the label language was buried, minimized, or not communicated effectively to prescribing physicians.
Key Takeaway: Forteo side effects lawsuits cover both cancer and non-cancer injuries, with plaintiffs arguing that Eli Lilly’s warnings were inadequate across the board.
Forteo Cancer Risk
The Forteo cancer risk is rooted in some of the most alarming preclinical data in pharmaceutical history. Animal studies showed that teriparatide caused bone tumors in nearly every rat tested at high doses and over long durations.
Here’s what makes the Forteo story unusual. Most drugs earn their black box warnings after reaching the market. Forteo had one from day one. The FDA saw the rat data and decided the cancer risk was so concerning that the strongest possible warning was required before a single prescription was written.
The rat studies showed that:
- Rats given teriparatide for nearly their entire lifespan developed osteosarcoma
- The tumor incidence was dose-dependent, meaning higher doses caused more cancers
- Even relatively low doses produced tumors at rates far above normal
Eli Lilly argued that the rat findings didn’t translate to humans. Rats have different bone biology. They grow bone continuously throughout life, while adult humans don’t. This biological difference is central to the company’s defense.
But post-market surveillance has complicated that argument. The FDA’s Adverse Event Reporting System (FAERS) has logged reports of osteosarcoma in human Forteo users. While the absolute numbers are small, critics say these cases validate the rat study concerns.
The recommended treatment duration was originally capped at 24 months specifically because of cancer fears. In 2020, the FDA extended the maximum to 24 months total lifetime exposure, but the black box warning remained.
Patients who used Forteo beyond two years may face higher risk, though the exact increase hasn’t been quantified in human studies.
Eli Lilly Forteo Lawsuit
The Eli Lilly Forteo lawsuit names one of the world’s largest pharmaceutical companies as the defendant. Eli Lilly and Company, headquartered in Indianapolis, Indiana, generated over $35 billion in revenue in recent years. Forteo has been a significant revenue contributor since its 2002 launch.
Plaintiffs accuse Eli Lilly of several specific failures:
- Failure to warn: Not adequately communicating cancer risks to patients and doctors
- Defective design: Marketing a drug with known carcinogenic potential without sufficient safeguards
- Negligence: Ignoring or downplaying post-market safety signals
- Fraud and misrepresentation: Allegedly minimizing cancer data in promotional materials
Eli Lilly has fought these claims aggressively. The company’s primary defense rests on two pillars. First, the black box warning existed from the start. Second, the rat study data doesn’t prove causation in humans.
The company has deep legal resources and a history of defending pharmaceutical litigation. Eli Lilly has previously settled large-scale drug lawsuits, including cases involving Zyprexa and Cymbalta. Those settlements totaled billions.
| Eli Lilly Lawsuit History | Drug | Settlement/Outcome |
|---|---|---|
| Zyprexa litigation | Zyprexa | $1.42 billion settlement |
| Cymbalta withdrawal cases | Cymbalta | Individual settlements reached |
| Forteo cancer claims | Forteo | Pending as of 2026 |
Whether Eli Lilly chooses to settle Forteo cases or fight them through trial remains unclear. The company’s history suggests it may settle once the plaintiff pool reaches a critical mass and the costs of continued litigation outweigh a global settlement.
Key Takeaway: Eli Lilly is a well-funded defendant with a track record of eventually settling large pharmaceutical lawsuits, which may signal future Forteo resolutions.
Forteo Black Box Warning
The Forteo black box warning is the most severe safety alert the FDA can place on a prescription drug. It appears as a bold, black-bordered box at the top of the prescribing information. For Forteo, this warning has been there since the drug’s first day on the market.
The black box states that teriparatide caused osteosarcoma in rats. It recommends limiting treatment duration and advises against prescribing Forteo to patients already at increased risk for bone cancer.
Specific groups warned against using Forteo include:
- Patients with Paget’s disease of bone
- Those with unexplained elevations of alkaline phosphatase
- Patients who have received prior radiation therapy involving the skeleton
- Children and young adults with open growth plates
- Anyone with a pre-existing bone cancer or bone metastases
The lawsuit debate centers on whether this warning was enough. Plaintiffs say a black box on the label is meaningless if drug reps downplay the risk during sales calls to physicians. They allege that Eli Lilly’s marketing strategy contradicted the warning’s intent.
Some plaintiffs report that their doctors had no idea about the black box. If a prescribing physician doesn’t know about the warning, the patient never learns about it either.
The legal concept here is called “learned intermediary.” Drug companies typically warn doctors, not patients directly. If the doctor wasn’t properly warned, the company can be held liable for the patient’s injuries.
Forteo FDA Warning History
The Forteo FDA warning history spans over two decades and reflects the agency’s ongoing concerns about cancer risk. Tracking this history helps explain why lawsuits are gaining traction in 2026.
| Year | FDA Action |
|---|---|
| 2002 | Forteo approved with black box warning for osteosarcoma risk based on rat studies |
| 2002-2009 | Post-market surveillance period begins; FDA monitors adverse event reports |
| 2009 | FDA reviews initial post-market osteosarcoma reports in humans |
| 2010 | Eli Lilly required to conduct a 15-year post-marketing surveillance study |
| 2020 | FDA revises label; removes the 2-year lifetime limit recommendation but keeps black box |
| 2021-2025 | Continued FAERS reports of osteosarcoma in human Forteo patients |
| 2026 | Litigation intensifies as more patients come forward after cancer diagnoses |
The 2020 label change is a contentious point. The FDA removed the strict two-year cap on treatment duration. Some argue this decision exposed more patients to prolonged cancer risk. Others say it reflected confidence that the human risk was lower than the rat studies suggested.
The 15-year post-marketing study that Eli Lilly was required to conduct has been closely watched. Preliminary data from that study has been mixed, with some findings that plaintiffs believe support their claims.
What’s telling is that the FDA never fully removed the black box warning. After more than 20 years on the market, the cancer concern remains prominent on the label. That persistence speaks volumes about the agency’s lingering worries.
Key Takeaway: The FDA has maintained its black box warning on Forteo for over 20 years, and the regulatory timeline provides strong supporting evidence for plaintiff claims.
Forteo Settlement Amounts
Forteo settlement amounts have not been publicly announced as part of a global settlement as of 2026 because the litigation hasn’t reached that stage yet. However, legal analysts and attorneys involved in the cases have provided estimated ranges based on comparable pharmaceutical lawsuits.
Individual case values depend heavily on the severity of injury. Here are projected settlement tiers based on attorney estimates and analogous litigation:
| Injury Level | Description | Estimated Settlement Range |
|---|---|---|
| Tier 1 (Highest) | Osteosarcoma diagnosis with surgery/amputation | $500,000 to $2,000,000+ |
| Tier 2 | Osteosarcoma diagnosis, treated with chemo only | $250,000 to $750,000 |
| Tier 3 | Other bone cancer diagnosis linked to Forteo | $100,000 to $500,000 |
| Tier 4 | Benign bone tumors requiring surgery | $50,000 to $200,000 |
| Tier 5 | Non-cancer serious side effects with lasting harm | $25,000 to $100,000 |
These numbers are estimates, not guarantees. Every case is different. The strength of your medical evidence, the duration of Forteo use, and the severity of your outcome all factor into your potential recovery.
Comparable pharmaceutical settlements provide useful benchmarks. Bone cancer cases from other drug lawsuits have settled in the six-figure to low-seven-figure range for individual plaintiffs.
If Eli Lilly agrees to a global settlement, the total fund could be substantial given the company’s resources and the severity of the alleged injuries.
Forteo Lawsuit Settlement
The Forteo lawsuit settlement process is still in its early stages in 2026. No global settlement has been reached, and individual case resolutions have been limited. But the trajectory of similar pharmaceutical lawsuits offers a roadmap for what might happen.
In a typical pharmaceutical mass tort, the settlement process follows a pattern:
- Filing phase: Plaintiffs file individual claims (ongoing now)
- Consolidation: Cases are grouped for pretrial proceedings, often through MDL
- Discovery: Both sides exchange documents, depose witnesses, and hire experts
- Bellwether trials: A small number of cases go to trial to test jury reactions
- Negotiation: Based on trial outcomes, parties negotiate a global settlement
- Distribution: Settlement funds are allocated to plaintiffs based on injury severity
Forteo litigation currently sits between steps 1 and 3. Filing continues, and discovery is advancing. No bellwether trials have occurred yet, but they could be scheduled by late 2026 or 2027.
The bellwether trial results will be critical. If juries side with plaintiffs and award large verdicts, Eli Lilly will face enormous pressure to settle. If the defense wins, settlement values could drop or the litigation could stall.
Think of bellwether trials as dress rehearsals. Both sides test their strongest arguments. The results set the tone for everything that follows.
Key Takeaway: The Forteo settlement process is still unfolding, and bellwether trial outcomes in late 2026 or 2027 could determine the ultimate value of all pending claims.
Forteo Lawsuit Payout Per Person
The Forteo lawsuit payout per person will vary dramatically depending on individual circumstances. There is no one-size-fits-all number. Your specific medical history, the strength of your evidence, and the severity of your injuries all shape your potential compensation.
Factors that increase payout value:
- Osteosarcoma diagnosis confirmed by pathology
- Longer Forteo use (especially beyond 24 months)
- No alternative explanation for the cancer (no prior radiation, no Paget’s disease)
- Severe treatment required (amputation, extensive surgery, chemotherapy)
- Significant lost income and quality of life impact
- Strong documentation of Forteo prescriptions and treatment timeline
Factors that decrease payout value:
- Pre-existing conditions that could independently cause bone cancer
- Short duration of Forteo use
- Weak medical records or gaps in documentation
- Other risk factors present (family history of bone cancer, radiation exposure)
| Payout Factor | Higher Payout | Lower Payout |
|---|---|---|
| Diagnosis | Osteosarcoma | Benign tumor |
| Treatment duration | 18-24+ months on Forteo | Under 6 months |
| Medical evidence | Complete records | Gaps in documentation |
| Alternative causes | None present | Multiple risk factors |
| Treatment required | Surgery/amputation | Monitoring only |
Attorney fees typically run between 33% and 40% of the settlement in contingency fee arrangements. Most Forteo attorneys work on contingency, meaning you pay nothing upfront. They collect their fee only if you win or settle.
After attorney fees and case costs, the net payout to the plaintiff is typically 60% to 67% of the gross settlement amount.
Who Qualifies for Forteo Lawsuit
Who qualifies for a Forteo lawsuit? You may be eligible if you used Forteo (teriparatide) and later developed osteosarcoma, bone cancer, or other serious bone-related health conditions. The strongest cases involve a confirmed cancer diagnosis following documented Forteo use.
General eligibility criteria include:
- You were prescribed and used Forteo (teriparatide) for osteoporosis or another condition
- You developed osteosarcoma, bone cancer, or bone tumors during or after Forteo treatment
- Your diagnosis occurred within a reasonable time after starting or completing Forteo use
- You have medical records documenting both the Forteo prescriptions and the cancer diagnosis
- Your state’s statute of limitations has not expired
Some cases may qualify even without a cancer diagnosis. Patients who developed other serious adverse effects like severe hypercalcemia leading to hospitalization or lasting kidney damage could potentially have claims, though these cases are harder to win.
| Eligibility Factor | Likely Qualifies | May Not Qualify |
|---|---|---|
| Took Forteo | Yes, documented use | No prescription records |
| Cancer diagnosis | Osteosarcoma or bone cancer | No diagnosis |
| Timing | Cancer within 2-10 years of use | Cancer decades before Forteo |
| Medical records | Complete treatment history | No documentation available |
| Statute of limitations | Within filing window | Deadline already passed |
Family members of deceased Forteo users may qualify for wrongful death claims. If a loved one died from osteosarcoma after using Forteo, the estate can pursue legal action on their behalf.
Key Takeaway: The strongest Forteo lawsuit candidates have documented Forteo use, a confirmed bone cancer diagnosis, and medical records connecting the two.
How to File a Forteo Lawsuit
How to file a Forteo lawsuit starts with one step: contacting an attorney who handles pharmaceutical product liability cases. You don’t need to navigate the legal system alone, and most Forteo attorneys offer free case evaluations.
Here’s the step-by-step process:
Step 1: Gather your records. Collect your pharmacy records showing Forteo prescriptions, medical records documenting your diagnosis, and any correspondence with your doctors about Forteo risks.
Step 2: Consult an attorney. Look for law firms with experience in pharmaceutical mass tort litigation. Many firms specializing in drug injury cases accept Forteo clients on a contingency basis.
Step 3: Case evaluation. The attorney reviews your medical history, Forteo usage, diagnosis, and timeline. They’ll assess whether your case meets the criteria for filing.
Step 4: Filing the complaint. If your case qualifies, the attorney files a complaint in the appropriate court. This document outlines your allegations against Eli Lilly and the damages you’re seeking.
Step 5: Discovery and litigation. Your case enters the legal process. You may need to provide medical records, undergo independent medical examinations, and participate in depositions.
| Step | What Happens | Your Role |
|---|---|---|
| Record gathering | Compile medical and pharmacy records | Active |
| Attorney consultation | Free case review | Active |
| Case evaluation | Attorney assesses case strength | Passive |
| Filing | Complaint filed in court | Passive (attorney handles) |
| Discovery | Evidence exchange between parties | Moderate (provide records, testimony) |
| Resolution | Settlement or trial | Passive until needed |
You don’t pay upfront in most cases. Contingency fee arrangements mean the attorney gets paid only if your case results in a settlement or verdict.
Forteo Lawsuit Deadline 2026
The Forteo lawsuit deadline in 2026 depends on your state’s statute of limitations for personal injury and product liability claims. There is no single national deadline. Each state sets its own filing window.
Most states give you between 2 and 6 years from the date you discovered (or should have discovered) your injury. This is called the “discovery rule.” The clock typically starts when you receive your cancer diagnosis, not when you first took Forteo.
| State | Statute of Limitations | Discovery Rule |
|---|---|---|
| California | 2 years | Yes, from discovery of injury |
| Texas | 2 years | Yes |
| New York | 3 years | Yes |
| Florida | 4 years | Yes |
| Illinois | 2 years | Yes |
| Pennsylvania | 2 years | Yes |
| Ohio | 2 years | Yes, with some exceptions |
This table shows only a few examples. Your state may have different rules, and exceptions can apply. Some states toll (pause) the statute of limitations if the defendant concealed information about the product’s dangers.
If you were diagnosed with osteosarcoma in 2024, many states would require you to file by 2026 or 2027 at the latest. Waiting too long is risky. Once the deadline passes, you lose your right to sue permanently.
The best approach is simple: don’t wait. Even if you think you might have a case, getting a free consultation now protects your rights. An attorney can tell you exactly when your deadline falls.
Key Takeaway: Every state has a different filing deadline, and the clock is ticking for patients diagnosed with bone cancer in recent years; act quickly to preserve your rights.
Frequently Asked Questions
Is there a class action lawsuit against Forteo in 2026?
Legal actions exist against Forteo in 2026, but they’re structured as individual product liability claims rather than a certified class action.
Cases may be consolidated into an MDL for pretrial efficiency.
The term “class action” is commonly used, but mass tort litigation more accurately describes the current Forteo cases.
How much money can I get from a Forteo lawsuit?
Estimated payouts range from $25,000 to over $2,000,000 depending on injury severity.
Osteosarcoma cases with surgery or amputation command the highest values.
Final amounts depend on your medical evidence, Forteo usage duration, and case strength.
What are the side effects of Forteo that led to lawsuits?
Osteosarcoma (bone cancer) is the primary side effect driving Forteo lawsuits.
Other reported side effects include hypercalcemia, severe joint pain, dizziness, and nausea.
The FDA placed a black box warning on Forteo at approval specifically because of the cancer risk.
What is the deadline to file a Forteo lawsuit?
The deadline depends on your state’s statute of limitations, typically 2 to 6 years from when you discovered your injury.
The clock usually starts at diagnosis, not at the time you used Forteo.
Filing sooner rather than later is strongly recommended since missing the deadline permanently bars your claim.
Does Forteo cause bone cancer?
Preclinical studies showed that teriparatide (the active ingredient in Forteo) caused osteosarcoma in rats.
Post-market reports have documented osteosarcoma cases in human Forteo users.
The FDA has maintained a black box warning about this cancer risk for over 20 years, and the connection remains the central issue in pending lawsuits.
This is a case worth watching closely. If you used Forteo and developed bone cancer or any serious bone condition, your window to act could be narrowing.
Gather your medical records. Reach out to a pharmaceutical litigation attorney. Get your free case evaluation before any deadlines pass.
The 2026 landscape for Forteo litigation is active and evolving. Staying informed gives you the best chance at holding Eli Lilly accountable
